# Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

> **NCT07283965** · — · NOT_YET_RECRUITING · sponsor: **University Hospital, Caen** · enrollment: 15000 (estimated)

## Conditions studied

- Chronic B-cell Malignancies
- BTK Inhibitors
- Cardiovascular Diseases

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT07283965
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-03-31
- **Target enrollment:** 15000 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283965, "Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07283965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*